EGFR and non-small cell lung carcinoma: EGFR-mutant NSCLC exhibited distinctive TME features in PD-L1 expression, tumor mutation burden (TMB), and CD8+ tumor infiltration lymphocytes (TILs) compared with wild type NSCLC [7].